Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on January 26, 2026, the round was led by Google Ventures (NASDAQ:GOOGL), with significant participation from NVentures, the venture capital arm of NVIDIA (NASDAQ:NVDA), alongside long-time [...]
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the company is currently navigating the "Keytruda Cliff"—the 2028 expiration of patents for its $30 billion-a-year blockbuster. While Merck has spent the last five [...]
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market value in a single trading session. This volatility was on full display in late January 2026 as Revolution Medicines (Nasdaq: RVMD) experienced a dramatic 20% stock [...]
Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for their experimental mRNA cancer vaccine. The results, stemming from the Phase 2b KEYNOTE-942 trial, demonstrated that the combination of Moderna’
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the pharmaceutical industry’s most feared obstacle: the "patent cliff." Following a "catapult year" in 2025, the healthcare giant is projecting
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based biotechnology giant is now aggressively shedding its image as a "one-hit wonder" vaccine maker. Following a volatile 2024 and 2025, the company has captured Wall [...]
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 22% gain over the past six months, beating the S&P 500 by 14.2 percentage points.
CEPI will provide Merck with $30 million and Merck will, in turn, leverage its joint venture with Wellcome, called Hilleman Laboratories, to develop an Ebola vaccine with an updated manufacturing process.
